Technical Analysis for GTBP - GT Biopharma Inc.

Grade Last Price % Change Price Change
grade C 0.111 -0.89% -0.0010
GTBP closed down 0.89 percent on Tuesday, January 28, 2020, on approximately normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Flat Up
Historical GTBP trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -0.89%
Crossed Above 50 DMA Bullish -0.89%
180 Bullish Setup Bullish Swing Setup -0.89%
Upper Bollinger Band Walk Strength -0.89%
Older signals for GTBP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors. It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.
Cancer Pain Immunology Immune System Monoclonal Antibodies Cancer Immunotherapy Stage Biopharmaceutical Technology Platforms Cancer Therapies Biochemistry Motion Sickness Immuno Oncology Products Myasthenia Gravis

Is GTBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.73
52 Week Low 0.065
Average Volume 116,892
200-Day Moving Average 0.1994
50-Day Moving Average 0.1107
20-Day Moving Average 0.0974
10-Day Moving Average 0.1002
Average True Range 0.0292
ADX 27.35
+DI 22.4480
-DI 10.0367
Chandelier Exit (Long, 3 ATRs ) 0.0924
Chandelier Exit (Short, 3 ATRs ) 0.1626
Upper Bollinger Band 0.1128
Lower Bollinger Band 0.0820
Percent B (%b) 0.94
BandWidth 31.6222
MACD Line -0.0007
MACD Signal Line -0.0041
MACD Histogram 0.0034
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1748
Resistance 3 (R3) 0.1762 0.1563 0.1641
Resistance 2 (R2) 0.1563 0.1401 0.1556 0.1606
Resistance 1 (R1) 0.1337 0.1301 0.1238 0.1323 0.1570
Pivot Point 0.1138 0.1138 0.1089 0.1131 0.1138
Support 1 (S1) 0.0912 0.0976 0.0813 0.0898 0.0650
Support 2 (S2) 0.0713 0.0876 0.0706 0.0614
Support 3 (S3) 0.0487 0.0713 0.0579
Support 4 (S4) 0.0473